Outcome Capital Launches the First Dedicated Ophthalmology Practice to Address the World’s Leading Cause of Disability

Appoints Paul Ryb Managing Director to Lead Firm’s Expansion

BOSTON – July 8, 2025 – Outcome Capital, LLC, a highly specialized life sciences and healthcare advisory and investment banking firm, today announced that Paul Ryb has been appointed Managing Director and will lead the firm’s dedicated ophthalmology practice, providing strategic guidance, transactional support, and advisory services to clients in the sector. As a highly experienced transaction expert, a leading visually impaired patient advocate, and an ophthalmic venture specialist, Paul has been on a unique and inspiring journey, demonstrating how to “live and succeed with sight-loss”, while supporting, advising and financing ophthalmic innovation across the drug, device, and technology markets for the last 15 years. With vision impairment impacting over 2.2 billion people globally and ranking as a leading cause of disability, the ophthalmology sector urgently requires innovation.

“This appointment aligns with Outcome’s strategy to address the rapidly growing ophthalmology segment through the first dedicated ophthalmology practice in the market to address eye disease, the leading cause of disability,” said Oded Ben-Joseph, PhD, MBA, Outcome’s Managing Partner. “On behalf of the entire Outcome team, I extend my congratulations to Paul and welcome him to this new role. His demonstrated leadership and exceptional experience and insight will strengthen our capabilities to assist innovative ophthalmology companies in their demand for venture support and a trusted collaborative partner to implement vital de-risking strategies, such as broader access to strategic opportunities, robust market intelligence, and seamless deal structuring. Paul has already exemplified these strengths, notably through his role in the Bausch + Lomb acquisition of ELIOS Vision, and in his support of numerous financings for ophthalmic ventures in collaboration with key strategics and venture capitalists.”

Recognized for its strategy-first, market-aligned approach, combining deep scientific and clinical expertise with strategic market insights, Paul Ryb brings Outcome Capital over 30 years of leadership across global investment banking, capital markets, and venture capital, along with deep expertise in ophthalmic innovation. As both a visually impaired patient advocate and a seasoned investor, his focus includes advancing drug and medical device development, diagnostic tools, and AI adoption.
Before joining Outcome Capital, Paul served as a Managing Director at Royal Bank of Scotland (NatWest Group) and other major banks, and has served on numerous public, commercial, and nonprofit boards, including the National Health Service (NHS) and Royal National Institute of the Blind (RNIB). Paul served as Vice Chair of The Macular Society UK for 12 years and currently sits on the Investment Committee for Fight for Sight – the UK’s largest supporter of Ophthalmic Research Grants.
Paul earned his degree in economics from the University of Manchester and is certified by UK’s Financial Conduct Authority (FCA). Outside of work, he is a World and British champion in visually impaired tennis and a black belt in Xen-Do kickboxing.
“I am privileged and excited to join Outcome Capital as a Managing Director and to be working with such a talented team of individuals. Establishing such a differentiated and specialized Ophthalmic Investment Banking Advisory Group will allow us to deliver real patient outcomes and move closer to solving one of the world’s greatest unmet needs – sight-loss!” said Paul Ryb. “By integrating my experience with Outcome’s track record and deep expertise in ophthalmology for sourcing innovation, financing and successful exits, we are uniquely positioned to deliver on our mission to support the most promising ophthalmology innovation programs through every stage of development and ultimately drive real patient outcomes.”

About Outcome Capital
Outcome Capital (outcomecapital.com) is a highly specialized life sciences and healthcare advisory and investment banking firm, providing innovative companies with a value-added, market-aligned approach to mergers & acquisitions, partnering and corporate finance. The firm leverages its proven ‘strategy-led execution’ approach to value enhancement by assisting management teams and their boards in navigating both financial and corporate markets and implementing the best path for success. The firm’s strength stems from its multi-disciplinary, industry experts who draw from their broad relationships and a wide range of scientific, operational, strategic and transactional expertise across the value chain. Comprised of former CEOs, business development executives, venture capitalists, PhD/MD-level scientists and clinicians, and experienced commercialization experts, Outcome’s team is driven to propel innovation from bench to bedside.

Contacts

Outcome Capital – Media
Michelle Linn
Linnden Communications
michelle@linndencom.com

Outcome Capital
Steve Holstein
SHolstein@outcomecapital.com